Psychotropic drug metabolism in the cancer patient: Clinical aspects of management of potential drug interactions

Psycho-Oncology

Volumn 7, Issue 4, 1998, Pages 307-320

  Kalash, Glenn R ^a  

^a JAMAICA HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIARRHYTHMIC AGENT; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; NAFCILLIN; NAPROXEN; NEFAZODONE; PACLITAXEL; PAROXETINE; PERCOCET; PIROXICAM; RIFAMPICIN; RISPERIDONE; RITONAVIR; SERTRALINE; TAMOXIFEN; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BINDING AFFINITY; BONE METASTASIS; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; PROSTATE CANCER; PSYCHOMOTOR DISORDER; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; MENTAL DISORDERS; NEOPLASMS; PSYCHOTROPIC DRUGS;

EID: 0031597103     PISSN: 10579249     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1611(199807/08)7:4<307::AID-PON366>3.0.CO;2-3     Document Type: Review

References (21)

1. Baumann, P. (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31, 444-469.
2. Bertz, R.J. and Granneman, G.R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32, 210-258.
3. Callahan, A.M., Marangell, L.B. and Ketter, T.A. (1996) Evaluating the clinical significance of drug interactions: a systemic approach. Harv. Rev. Psychiatry 4, 153-158.
4. DeVane, C.L. (1994) Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry 55(Suppl. 12), 38-45.
5. Eichelbaum, M. and Gross, S.A. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol. Ther. 46, 377-394.
6. Ereshefsky, L., Riesenman, C. and Lam, Y.W.F. (1996) Serotonin selective reuptake inhibitor drug interac-tions and the cytochrome p450 system. J. Clin. Psychiatry 57(Suppl. 8), 17-24.
7. Guengerich, F.P. (1992) Characterization of human cytochrome p450 enzymes. FASEB J. 6, 745-748.
8. Harvey, A.T. and Preskorn, S.H. (1996a) Cytochrome p450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J. Clin. Psychopharmacol. 16, 273-285.
9. Harvey, A.T. and Preskorn, S.T. (1996b) Cytochrome p450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J. Clin. Psychopharmacol. 16, 345-355.
10. Krishnan, K.R., Steffens, D.C. and Doraiswamy, P.M. (1996) Psychotropic drug interactions. Prim. Psychiatry 1, 21-45.
11. Nakamura, K., Goto, F., Ray, W.A., McAllister, C.B., Jacqz, E., Wilkinson, G.R. and Branch, R.A. (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38, 402-408.
12. Nemeroff, C.B., DeVane, C.L. and Pollock, B.G. (1993) Newer antidepressants and the cytochrome p450 system. Am. J. Psychiatry 153, 311-320.
13. Pirmohamed, M., Madden, S. and Park, B.K. (1996) Idiosyncratic drug reactions - metabolic bioactivation as a pathogenic mechanism. Clin. Pharmacokinet. 31, 215-230.
14. Pollack, B.G., Perel, J.M., Kirshner, M., Altieri, L.P., Yeager, A.L. and Reynolds, C.F. III. (1991) S-Mephenytoin 4-hydroxylation in Older Americans. Eur. J. Clin. Pharmacol. 40, 609-611.
15. Pollack, B.G. (1994) Recent developments in drug metabolism of relevance to psychiatrists. Harv. Rev. Psychiatry 2, 204-213.
16. Preskorn, S.H. and Magnus, R.D. (1994) Inhibition of hepatic p-450 isoenzymes by selective serotonin reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharm. Bull. 30, 251-259.
17. Preskorn, S.H. (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors - an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 32(Suppl. 1), 1-21.
18. Ratain, M.J. (1997) Cancer: Principles & Practices of Oncology (5th edn.); Pharmacology of Cancer Chemotherapy (Chapter 19, 375-385) (DeVita, Jr., V.T., Hellman, S. and Rosenberg, S. Eds). Lippincott-Raven Publishers, Philadelphia.
19. Riesenman, C. (1995) Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal. Pharmacotherapy 15(Suppl.), 84S-99S.
20. Rosenbaum, J.F. (1995) Managing selective serotonin reuptake inhibitor - drug interactions in clinical practice. Clin. Pharmacokinet. 29(Suppl. 1), 53-59.
21. Wilkinson, G.R., Guengerich, F.P. and Branch, R.A. (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53-76.